Should I buy or sell ThermoGenesis stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ThermoGenesis in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" THMO shares. View THMO analyst ratings or view top-rated stocks .

What is ThermoGenesis' stock price target for 2024?

1 Wall Street research analysts have issued twelve-month price targets for ThermoGenesis' shares. Their THMO share price targets range from $5.00 to $5.00. On average, they expect the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 654.6% from the stock's current price. View analysts price targets for THMO or view top-rated stocks among Wall Street analysts .

How have THMO shares performed in 2024?

ThermoGenesis' stock was trading at $0.6010 on January 1st, 2024. Since then, THMO shares have increased by 10.2% and is now trading at $0.6626. View the best growth stocks for 2024 here .

Are investors shorting ThermoGenesis?

ThermoGenesis saw a decline in short interest in March. As of March 31st, there was short interest totaling 55,200 shares, a decline of 31.3% from the March 15th total of 80,400 shares. Based on an average daily volume of 86,100 shares, the days-to-cover ratio is currently 0.6 days. Approximately 3.1% of the shares of the company are short sold. View ThermoGenesis' Short Interest .

When is ThermoGenesis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our THMO earnings forecast .

How were ThermoGenesis' earnings last quarter?

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) posted its earnings results on Friday, November, 12th. The company reported ($6.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.60) by $3.15. The company had revenue of $3.16 million for the quarter, compared to analyst estimates of $3.06 million. ThermoGenesis had a negative trailing twelve-month return on equity of 402.05% and a negative net margin of 148.15%. During the same quarter last year, the firm earned ($16.65) EPS.

When did ThermoGenesis' stock split?

ThermoGenesis shares reverse split on the morning of Friday, December 23rd 2022. The 1-45 reverse split was announced on Friday, December 23rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of ThermoGenesis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ThermoGenesis investors own include FuelCell Energy (FCEL) , Inovio Pharmaceuticals (INO) , Co-Diagnostics (CODX) , NVIDIA (NVDA) , OPKO Health (OPK) , Advanced Micro Devices (AMD) , Dynavax Technologies (DVAX) , Gilead Sciences (GILD) , Pfizer (PFE) and AbbVie (ABBV) .

How do I buy shares of ThermoGenesis?

Shares of THMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:THMO

ThermoGenesis (THMO) Stock Price, News & Analysis

→ Your Money is Not Safe (From American Alternative) (Ad)

Free THMO Stock Alerts

$0.66

+0.01 (+1.53%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.62
▼
$0.72
50-Day Range: $0.62
▼
$1.09
52-Week Range: $0.36
▼
$2.44

Volume: 8,586 shs
Average Volume: 78,085 shs
Market Capitalization: $2.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Get ThermoGenesis alerts:

ThermoGenesis MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 654.6% Upside
$5.00 Price Target
Short Interest: Healthy
3.08% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.35) to $0.08 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.77 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
ThermoGenesis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
ThermoGenesis has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.08% of the float of ThermoGenesis has been sold short.
Short Interest Ratio / Days to Cover
ThermoGenesis has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ThermoGenesis has recently decreased by 31.34%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ThermoGenesis does not currently pay a dividend.
Dividend Growth
ThermoGenesis does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for THMO.

0.6

News and Social Media Coverage

News Sentiment
ThermoGenesis has a news sentiment score of -0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for ThermoGenesis this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for THMO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ThermoGenesis insiders have not sold or bought any company stock.
Percentage Held by Insiders
78.00% of the stock of ThermoGenesis is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 5.78% of the stock of ThermoGenesis is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for ThermoGenesis are expected to grow in the coming year, from ($4.35) to $0.08 per share.
Price to Book Value per Share Ratio
ThermoGenesis has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About ThermoGenesis Stock (NASDAQ:THMO)

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

THMO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

THMO Stock News Headlines

February 27, 2024 | finance.yahoo.com

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Is About To Turn The Corner

January 10, 2024 | thestreet.com

ThermoGenesis Holdings, Inc.

April 20, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

December 16, 2023 | benzinga.com

ThermoGenesis Holdings Stock (NASDAQ:THMO) Dividends: History, Yield and Dates

December 8, 2023 | finance.yahoo.com

Shareholders Will Probably Hold Off On Increasing ThermoGenesis Holdings, Inc.'s (NASDAQ:THMO) CEO Compensation For The Time Being

November 21, 2023 | benzinga.com

ThermoGenesis Holdings Recent Insider Activity

November 15, 2023 | finanznachrichten.de

ThermoGenesis Holdings, Inc.: ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 14, 2023 | finance.yahoo.com

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Q3 2023 Earnings Call Transcript

April 20, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

November 13, 2023 | finance.yahoo.com

ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 12, 2023 | msn.com

ThermoGenesis Q3 Earnings Preview

November 12, 2023 | markets.businessinsider.com

Here's what Wall Street expects from ThermoGenesis's earnings report

November 12, 2023 | morningstar.com

ThermoGenesis Holdings Inc THMO

November 10, 2023 | benzinga.com

ThermoGenesis Holdings Earnings Preview

November 8, 2023 | finance.yahoo.com

ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide a Corporate Strategic Update

October 27, 2023 | bizjournals.com

ThermoGenesis opens shared lab space for immunotherapy medical startups

October 26, 2023 | finance.yahoo.com

ThermoGenesis to Open a New 35,500 Square Foot ReadyStart-IncuStart cGMP Facility in Greater Sacramento

September 6, 2023 | finance.yahoo.com

ThermoGenesis Holdings to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 12, 2023 | finance.yahoo.com

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Q2 2023 Earnings Call Transcript

August 11, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on ThermoGenesis Holdings (THMO)

August 11, 2023 | finanznachrichten.de

ThermoGenesis Holdings, Inc.: ThermoGenesis Holdings Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 11, 2023 | finance.yahoo.com

ThermoGenesis Holdings Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 8, 2023 | finance.yahoo.com

ThermoGenesis Holdings to Announce Financial Results for the Second Quarter ended June 30, 2023 and Provide a Corporate Strategic Update

July 29, 2023 | fool.com

ThermoGenesis (NASDAQ: THMO)

July 17, 2023 | finance.yahoo.com

ThermoGenesis Expands Board of Directors with the Appointments of Dr. Biao Xi and Dr. James Xu

May 17, 2023 | msn.com

HC Wainwright & Co. Reiterates ThermoGenesis Holdings (THMO) Buy Recommendation

May 16, 2023 | finanznachrichten.de

ThermoGenesis Holdings, Inc.: ThermoGenesis Holdings Announces First Quarter 2023 Financial Results and Provides Corporate Update

See More Headlines

Receive THMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ThermoGenesis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/20/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Laboratory apparatus & furniture
Sub-Industry: N/A
Current Symbol: NASDAQ:THMO
CUSIP: N/A
CIK: 811212
Web: www.thermogenesis.com
Phone: (916) 858-5100
Fax: 916-858-5199
Employees: 40
Year Founded: 1986

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +654.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,270,000.00
Net Margins: -148.15%
Pretax Margin: -153.29%
Return on Equity: -402.05%
Return on Assets: -78.71%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.78
Quick Ratio: 0.57

Sales & Book Value

Annual Sales: $9.44 million
Price / Sales: 0.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.20 per share
Price / Book: 0.21

Miscellaneous

Outstanding Shares: 3,140,000
Free Float: 690,000
Market Cap: $2.08 million
Optionable: Not Optionable
Beta: 2.41

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Xiaochun Xu M.B.A. (Age 53)
Ph.D., Chairman of the Board & CEO
Comp: $699k
Mr. Jeffery Cauble CPA (Age 51)
CFO & Corporate Secretary
Comp: $325k
Ms. Haihong Zhu (Age 58)
Chief Operating Officer
Comp: $554k

Key Competitors

View All Competitors

Insiders

Xiaochun Xu
Sold 600,000 shares
Total: $612,000.00 ($1.02/share)

View All Insider Transactions

THMO Stock Analysis - Frequently Asked Questions

Should I buy or sell ThermoGenesis stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ThermoGenesis in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" THMO shares.
View THMO analyst ratings or view top-rated stocks.
What is ThermoGenesis' stock price target for 2024?: 1 Wall Street research analysts have issued twelve-month price targets for ThermoGenesis' shares. Their THMO share price targets range from $5.00 to $5.00. On average, they expect the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 654.6% from the stock's current price.
View analysts price targets for THMO or view top-rated stocks among Wall Street analysts.
How have THMO shares performed in 2024?: ThermoGenesis' stock was trading at $0.6010 on January 1st, 2024. Since then, THMO shares have increased by 10.2% and is now trading at $0.6626.
View the best growth stocks for 2024 here.
Are investors shorting ThermoGenesis?: ThermoGenesis saw a decline in short interest in March. As of March 31st, there was short interest totaling 55,200 shares, a decline of 31.3% from the March 15th total of 80,400 shares. Based on an average daily volume of 86,100 shares, the days-to-cover ratio is currently 0.6 days. Approximately 3.1% of the shares of the company are short sold.
View ThermoGenesis' Short Interest.
When is ThermoGenesis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our THMO earnings forecast.

How were ThermoGenesis' earnings last quarter?: ThermoGenesis Holdings, Inc. (NASDAQ:THMO) posted its earnings results on Friday, November, 12th. The company reported ($6.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.60) by $3.15. The company had revenue of $3.16 million for the quarter, compared to analyst estimates of $3.06 million. ThermoGenesis had a negative trailing twelve-month return on equity of 402.05% and a negative net margin of 148.15%. During the same quarter last year, the firm earned ($16.65) EPS.
When did ThermoGenesis' stock split?: ThermoGenesis shares reverse split on the morning of Friday, December 23rd 2022. The 1-45 reverse split was announced on Friday, December 23rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
What other stocks do shareholders of ThermoGenesis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ThermoGenesis investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), Co-Diagnostics (CODX), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Pfizer (PFE) and AbbVie (ABBV).
How do I buy shares of ThermoGenesis?: Shares of THMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:THMO) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial